The Royal Melbourne Hospital

Running trials

• Recruiting

  Study to Test Effects and Safety of RO7568282 in Early Symptomatic Alzheimer's Disease

  NCT07781657· Phase 2· Hoffmann-La Roche· Source

• Not yet recruiting

  AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

  NCT07931573· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  To Evaluate the Effects of Cevostamab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

  NCT07629583· Phase 1· Genentech, Inc.· Source

• Not yet recruiting

  An Online Tailored Cognitive Therapy-Based Intervention for Depression in Multiple Sclerosis: ACTION-MS Online

  NCT07875309· University of Melbourne· Source

• Recruiting

  A Study in Adults With Geographic Atrophy

  NCT07606365· Phase 2· Sitala Bio LTD· Source

• Active, not recruiting

  Functional Outcomes and Control Using Synchron BCI - Australia

  NCT07533903· Synchron, Inc.· Source

• Recruiting

  A First-in-human Study of the Effects of SRP-1005 in Participants With Huntington's Disease

  NCT07536061· Phase 1· Sarepta Therapeutics, Inc.· Source

• Enrolling by invitation

  An Extension of SKY-0515 in Participants With Huntington's Disease

  NCT07537075· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Recruiting

  Conquer-AF Protocol for Redo Ablation Procedures in Recurrent Paroxysmal and Persistent Atrial Fibrillation Using the Sphere-9 Catheter and Affera Ablation System (Conquer-AF)

  NCT07298473· Medtronic Cardiac Ablation Solutions· Source

• Not yet recruiting

  Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)

  NCT07527819· Peter MacCallum Cancer Centre, Australia· Source

• Recruiting

  A Gaucher Disease Gene Therapy Trial With FLT201

  NCT07223944· Phase 3· Spur Therapeutics· Source

• Recruiting

  A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)

  NCT07291076· Phase 1/2· Bristol-Myers Squibb· Source

• Recruiting

  Early Feasibility Study (EFS) of the 'CAROL' for Treatment of Lung Cancer Stage 1

  NCT07122258· Tau Medical Australia Pty Ltd· Source

• Recruiting

  A Study to Test if Tenecteplase Helps People to Recover From an Acute Stroke When Given More Than 4.5 Hours After the Person Was Last Seen Well

  NCT07361302· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)

  NCT07222332· Phase 3· Eli Lilly and Company· Source

• Not yet recruiting

  Evaluating Safe Ketone Thresholds To Minimise Ketosis in People With Type 1 Diabetes Using Dapagliflozin

  NCT07225465· Phase 2· St Vincent's Hospital Melbourne· Source

• Recruiting

  A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults

  NCT07222137· Phase 3· Eli Lilly and Company· Source

• Recruiting

  Study of DONQ52 in Active Celiac Disease

  NCT07239336· Phase 2· Chugai Pharmaceutical· Source

• Recruiting

  SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes

  NCT07187531· Phase 2· SAb Biotherapeutics, Inc.· Source

• Recruiting

  A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease

  NCT07174310· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RG6496 in Huntington's Disease

  NCT07246941· Phase 1· Hoffmann-La Roche· Source

• Recruiting

  A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

  NCT07165028· Phase 3· Eli Lilly and Company· Source

• Recruiting

  PRIORITY-CONNECT 2 Trial

  NCT06976710· Surgical Outcomes Research Centre (SOuRCe)· Source

• Active, not recruiting

  A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

  NCT07196748· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  A PHASE II PROSPECTIVE RANDOMIZED DOUBLE-MASKED CONTROLLED STUDY ASSESSING THE SAFETY & EFFICACY OF RHPRG4 (450 µG/ML RECOMBINANT HUMAN PROTEOGLYCAN 4) COMPARED TO VEHICLE FOR THE TREATMENT OF SJÖGREN'S RELATED DRY EYE DISEASE

  NCT07118241· Phase 2· Lubris Bio Pty Ltd· Source

• Recruiting

  Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study

  NCT07055542· University of Melbourne· Source

• Active, not recruiting

  A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

  NCT07076199· Phase 3· Novo Nordisk A/S· Source

• Recruiting

  Randomized, Double Blind, Placebo-controlled Phase 2 Study in Adults With Celiac Disease

  NCT06982963· Phase 2· Forte Biosciences, Inc.· Source

• Recruiting

  Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies

  NCT07177352· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)

  NCT07082725· Phase 3· Azafaros B.V.· Source

• Recruiting

  A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis

  NCT07054515· Phase 3· Azafaros B.V.· Source

• Recruiting

  A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

  NCT06944522· Phase 3· BlueRock Therapeutics· Source

• Recruiting

  A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

  NCT06782490· Phase 2· Celgene· Source

• Active, not recruiting

  Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System

  NCT06735534· Boston Scientific Corporation· Source

• Recruiting

  Safety and Efficacy of OD-07656 and of Subsequent Vedolizumab Therapy in Moderately to Severely Active Ulcerative Colitis

  NCT06850727· Phase 2· Odyssey Therapeutics, Inc.· Source

• Active, not recruiting

  Study of SKY-0515 for Safety, Efficacy, and Pharmacodynamics in Participants With Huntington's Disease

  NCT06873334· Phase 2/3· Skyhawk Therapeutics, Inc.· Source

• Active, not recruiting

  Pomalidomide as an Immune-enhancing Agent for the Control of HIV

  NCT06660498· Phase 1/2· University of Aarhus· Source

• Recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease

  NCT06819891· Phase 3· Hoffmann-La Roche· Source

• Active, not recruiting

  A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis

  NCT06934226· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Diagnostic Performance Study of the EMVision Emu™ Brain Scanner in the Detection of Intracranial Hemorrhage in Suspected Stroke Patients

  NCT06999122· EMVision Medical Devices Ltd· Source

• Recruiting

  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GT-02287 in Parkinson's Disease

  NCT06732180· Phase 1· Gain Therapeutics, Inc.· Source

• Recruiting

  Implementing Surgery School Prehabilitation Using Telehealth

  NCT06631872· University of Melbourne· Source

• Recruiting

  A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus

  NCT06613360· Phase 1· Cullinan Therapeutics Inc.· Source

• Active, not recruiting

  Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease

  NCT06760637· Phase 3· Pfizer· Source

• Recruiting

  RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures

  NCT06798896· Phase 2· Supernus Pharmaceuticals, Inc.· Source

• Active, not recruiting

  A Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06588855· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

  NCT06667908· Phase 2· Johnson & Johnson Enterprise Innovation Inc.· Source

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Active, not recruiting

  A Study of Remternetug (LY3372993) in Early Alzheimer's Disease (TRAILRUNNER-ALZ 3)

  NCT06653153· Phase 3· Eli Lilly and Company· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

Showing 50 of 129.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Stroke8 recruiting
• Epilepsy5 recruiting
• Type 1 diabetes5 recruiting
• Huntington's disease4 recruiting
• Lung cancer4 recruiting
• Parkinson disease4 recruiting
• Fatty liver disease (MASLD/MASH)3 recruiting
• Alzheimer disease2 recruiting
• Coeliac disease2 recruiting
• Crohn's disease2 recruiting
• Heart failure2 recruiting
• Lupus (SLE)2 recruiting
• Multiple sclerosis2 recruiting
• Prostate cancer2 recruiting
• Type 2 diabetes2 recruiting
• Asthma1 recruiting
• Atrial fibrillation1 recruiting
• Bladder cancer1 recruiting
• Childhood cancers1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• Coronary artery disease1 recruiting
• Depression1 recruiting
• Dystonia1 recruiting
• Eosinophilic oesophagitis1 recruiting
• Essential tremor1 recruiting
• Gaucher disease1 recruiting
• Hepatitis B1 recruiting
• Liver and biliary tract cancer1 recruiting
• Liver cirrhosis1 recruiting
• Macular degeneration1 recruiting
• Mild cognitive impairment1 recruiting
• Mitochondrial disease1 recruiting
• Myelodysplastic syndromes1 recruiting
• Myeloproliferative neoplasms1 recruiting
• Neuroendocrine tumours1 recruiting
• Osteoporosis1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting
• Peripheral artery disease1 recruiting
• Sjögren's disease1 recruiting
• Triple-negative breast cancer1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Terminated

  An Open-label Extension Safety Study of MELAS Patients Who Completed TIS6463-203 (PRIZM)

  NCT06961344· Phase 2· Tisento Therapeutics· Source

• Completed

  A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recovery After Acute Ischaemic Stroke

  NCT06987643· Phase 2· EIP Pharma Inc· Source

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· atai Therapeutics, Inc.· Source

• Completed

  A Study of Medical Cannabis Aerosol Via the Fixed-dose Syqe Inhaler as an Add-on Treatment of Diabetic Peripheral Neuropathic Pain (DPNP)

  NCT06490445· Phase 2· Syqe Medical· Source

• Withdrawn

  Efficacy and Safety of Volenrelaxin in Adults With Chronic Kidney Disease

  NCT06598631· Phase 2· Eli Lilly and Company· Source

• Completed

  A Phase 2b Study of Zagociguat in Patients With MELAS

  NCT06402123· Phase 2· Tisento Therapeutics· Source

• Completed

  Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

  NCT06667414· Hoffmann-La Roche· Source

• Completed

  FOCALFLEX (CE Mark) Study

  NCT06271967· Abbott Medical Devices· Source

• Completed

  Feasibility Assessment of the Wellumio 'Axana' 0.1T Portable MRI Device

  NCT07751328· Wellumio R&D Australia Pty Ltd· Source

• Completed

  VOLT-AF IDE Clinical Study

  NCT06223789· Abbott Medical Devices· Source

• Completed

  A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes

  NCT06326047· Phase 2· Novo Nordisk A/S· Source

• Completed

  A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor

  NCT06221969· Phase 3· Novo Nordisk A/S· Source

• Completed

  A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

  NCT06077864· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment

  NCT06088043· Phase 3· Takeda· Source

• Completed

  BPL-003 Efficacy and Safety in Treatment Resistant Depression

  NCT05870540· Phase 2· Beckley Psytech Limited· Source

• Completed

  A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke

  NCT05953480· Phase 2· Shionogi· Source

• Completed

  First in Human Study to Assess an Implant to Treat Severe Emphysema

  NCT05854550· Apreo Health, Inc.· Source

• Completed

  Insulin and Abatacept in Recently-diagnosed Type 1 Diabetes

  NCT05742243· Phase 2· Melbourne Health· Source

• Completed

  A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke

  NCT05686070· Phase 3· Bayer· Source

• Completed

  A Study Assessing Rocatinlimab (AMG 451) Monotherapy in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Horizon)

  NCT05651711· Phase 3· Amgen· Source

• Completed

  A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures

  NCT05614063· Phase 3· Xenon Pharmaceuticals Inc.· Source

• Completed

  ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1

  NCT05507203· Phase 3· Abivax S.A.· Source

• Terminated

  A Study of Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of KAN-101 in Celiac Disease (ACeD-it)

  NCT05574010· Phase 1/2· Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA· Source

• Terminated

  Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer

  NCT05425862· Phase 1· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy

  NCT05174221· Phase 1· Takeda· Source

• Completed

  A Study of Eptinezumab in Participants With Migraine and Medication Overuse Headache

  NCT05452239· Phase 4· H. Lundbeck A/S· Source

• Completed

  Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

  NCT04530123· Phase 2· Takeda· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Biogen· Source

• Terminated

  Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular Carcinoma

  NCT05359861· Phase 2· Coherus Oncology, Inc.· Source

• Completed

  Adjunctive GNX Treatment Compared With Placebo in Children and Adults With TSC-related Epilepsy

  NCT05323734· Phase 3· Marinus Pharmaceuticals· Source

• Terminated

  Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

  NCT05305040· Phase 2/3· AlloVir· Source

• Completed

  Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

  NCT05203224· Phase 2· University of Melbourne· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease

  NCT04994483· Phase 3· Cassava Sciences, Inc.· Source

• Terminated

  A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age

  NCT05085366· Phase 3· ModernaTX, Inc.· Source

• Completed

  Hepatocellular Carcinoma Imaging Using PSMA PET/CT

  NCT05095519· Phase 2· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  Study of WVE-003 in Patients With Huntington's Disease

  NCT05032196· Phase 1/2· Wave Life Sciences USA, Inc.· Source

• Completed

  A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial

  NCT04876391· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study to Evaluate the Safety and Efficacy of Selgantolimod (SLGN)-Containing Combination Therapies for the Treatment of Chronic Hepatitis B (CHB)

  NCT04891770· Phase 2· Gilead Sciences· Source

• Completed

  A Study to Test Safety and Efficacy of Survodutide (BI456906) in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

  NCT04771273· Phase 2· Boehringer Ingelheim· Source

• Completed

  Study To Assess Adverse Events and Change in Disease Activity Of 24-hour Continuous Subcutaneous Infusion Of ABBV-951 In Adult Participants With Advanced Parkinson's Disease

  NCT04750226· Phase 3· AbbVie· Source

• Terminated

  IMCY-0098 Proof of ACtion in Type 1 Diabetes (IMPACT Study)

  NCT04524949· Phase 2· Imcyse SA· Source

• Completed

  A Safety and Efficacy Study of Intravenous (IV) Elezanumab Assessing Change in Neurologic Function in Adult Participants With Acute Ischemic Stroke

  NCT04309474· Phase 2· AbbVie· Source

• Completed

  Baricitinib in New-onset Type 1 Diabetes

  NCT04774224· Phase 2· St Vincent's Institute of Medical Research· Source

• Terminated

  Extending the Time Window for Tenecteplase by Effective Reperfusion in Patients with Large Vessel Occlusion

  NCT04454788· Phase 3· University of Melbourne· Source

• Terminated

  Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C Trial

  NCT04316013· Phase 3· Peter MacCallum Cancer Centre, Australia· Source

• Completed

  Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

  NCT04392154· Phase 3· Eli Lilly and Company· Source

• Terminated

  A Study to Evaluate Safety and Tolerability of Aducanumab in Participants With Alzheimer's Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

  NCT04241068· Phase 3· Biogen· Source

• Recruiting

  Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

  NCT03573089· The University of Queensland· Source

• Terminated

  Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

  NCT04171141· Phase 1· Pfizer· Source

Showing 50 of 73.

Conditions

Diseases this institution publishes on or runs trials for.

• Stroke138 works · 21 trials
• Atrial fibrillation62 works · 7 trials
• Prostate cancer50 works · 4 trials
• Multiple sclerosis47 works · 4 trials
• Epilepsy43 works · 10 trials
• Multiple myeloma31 works · 2 trials
• Type 1 diabetes22 works · 10 trials
• Chronic lymphocytic leukaemia18 works · 2 trials
• Cytomegalovirus infection12 works · 2 trials
• Hodgkin lymphoma10 works · 0 trials
• Follicular lymphoma9 works · 0 trials
• Myelodysplastic syndromes9 works · 1 trial
• Coeliac disease8 works · 4 trials
• Ventricular tachycardia8 works · 0 trials
• Mantle cell lymphoma7 works · 0 trials
• Myeloproliferative neoplasms6 works · 1 trial
• Fabry disease5 works · 6 trials